Skip to main content
  • Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment.  Check your account now to learn when your revalidation is due. More information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Meeting Results June 2, 2010

Drug Name Review Type Committee Recommendation Prior Approval Status � Final Determination
Victoza New Drug Initial Review Require Prior Approval Prior Approval Required
Kalbitor New Drug Initial Review Remove Prior Approval Requirement Prior Approval Required
Intuniv New Drug Initial Review Require Prior Approval Prior Approval Required
Fanapt New Drug Initial Review Require Prior Approval Prior Approval Required
Effient New Drug Initial Review Require Prior Approval Prior Approval Required
Ampyra New Drug Initial Review Require Prior Approval Prior Approval Required
Xifaxan 550 New Drug Initial Review Require Prior Approval Prior Approval Required
Cayston New Drug Initial Review Require Prior Approval Prior Approval Required
Renvela New Drug Appeal Remove Prior Approval Requirement Prior Approval Required
Byetta New Drug Appeal Remove Prior Approval Requirement Prior Approval Required
Invega Sustenna New Drug Appeal Remove Prior Approval Requirement Prior Approval Required
Multaq New Drug Appeal Require Prior Approval Prior Approval Required
Twynsta New Drug Appeal Require Prior Approval Prior Approval Required
Zemplar New Drug Appeal Require Prior Approval Prior Approval Required
Toviaz New Drug Appeal Require Prior Approval Prior Approval Required
Vivitrol New Drug Appeal Removed from Agenda Prior to Mtg Prior Approval Required